Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Instagram Outage Disrupts Thousands of U.S. Users 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
SAN DIEGO, Aug. 29, 2017 -- Oxeia Biopharmaceuticals, Inc. has been invited to present at the 2017 Gateway Conference, which is being held on September 6-7, 2017 at the Four Seasons Hotel San Francisco.
Oxeia management is scheduled to present on Wednesday, September 6 at 2:00 pm Pacific Time, with one-on-one meetings held throughout the conference. The presentation will be webcast live and available for replay in the Investor Relations section of Oxeia’s website at www.oxeiabiopharma.com or on the Gateway Conference website at www.gateway-conference.com/presenters. To receive additional information, request an invitation or to schedule a one-on-one meeting, please email [email protected].
About the Gateway Conference
The 6th Annual Gateway Conference is an invite-only conference presented by Liolios, which brings together the most compelling companies with the nation’s top institutional investors and analysts. This year’s event features more than 100 companies from a number of growth industries, including technology, business and financial services, consumer, digital media, clean technology and life sciences. The format has been designed to give attendees direct access to senior management via company presentations, Q&A sessions and one-on-one meetings. For more information, visit www.gateway-conference.com or www.liolios.com.
About Oxeia Biopharmaceuticals, Inc.
Oxeia Biopharmaceuticals, Inc. is a privately held clinical stage biotechnology company headquartered in San Diego, CA. The company is focused on developing treatments for concussions and other acute neurotrauma conditions. Oxeia’s lead program, OXE-103, uniquely targets the metabolic dysfunction and subsequent neurotrauma underlying acute concussion pathophysiology. Oxeia anticipates initiating Phase 2 studies for OXE-103 in concussion and additional neurological indications in early 2018. The program has maintained a strong safety profile across nine previous clinical studies totaling 345 patients.
Contact: Kartik Shah Chief Business Officer Oxeia Biopharmaceuticals, Inc [email protected] 207.232.2863 Marek Ciszewski, J.D. Liolios, Inc. [email protected] 949.574.3860
